OBSCN and allergic asthma: Additionally, the binding energy of midecamycin to OBSCN was −17.99 kcal/mol, indicating a strong molecular interaction, suggesting that it may influence the pathogenesis of allergic asthma by modulating OBSCN-related signaling pathways.